BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res. 2018;11:83-94. [PMID: 29707074 DOI: 10.14740/gr990w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
2 Raudonis T, Gliebute A, Grigaityte AG, Lukosiunaite Z, Karmaziene T, Grigaitiene J. A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology. Medicina (Kaunas) 2020;56:E275. [PMID: 32512854 DOI: 10.3390/medicina56060275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [PMID: 34904028 DOI: 10.4254/wjh.v13.i11.1534] [Reference Citation Analysis]
4 Li M, Lan L, Zhang S, Xu Y, He W, Xiang D, Liu D, Ren X, Zhang C. IL-6 downregulates hepatic carboxylesterases via NF-κB activation in dextran sulfate sodium-induced colitis. Int Immunopharmacol 2021;99:107920. [PMID: 34217990 DOI: 10.1016/j.intimp.2021.107920] [Reference Citation Analysis]
5 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Reference Citation Analysis]
7 Hokama A, Arakaki S, Ishino S, Nakagawa Y, Tabata S, Agarie D, Kuwae S, Zukeyama R, Maeshiro T, Tsuruta Y, Matsuzaki A, Wada N, Takatsuki M, Fujita J. Hepatocellular Carcinoma in a Patient With Crohn's Disease. Cureus 2021;13:e16570. [PMID: 34430172 DOI: 10.7759/cureus.16570] [Reference Citation Analysis]
8 Yan Y, Xing C, Xiao Y, Shen X, Zhang Z, He C, Shi JB, Liu M, Liu X. Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease In Vivo. J Med Chem 2022. [PMID: 35536548 DOI: 10.1021/acs.jmedchem.2c00356] [Reference Citation Analysis]
9 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
10 Yaccob A, Mari A. Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterol 2019;10:309-15. [PMID: 31281626 DOI: 10.1136/flgastro-2018-101037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Rivera-Izquierdo M, Valero-Ubierna MDC, Nieto-Gómez P, Martínez-Bellón MD, Fernández-Martínez NF, Barranco-Quintana JL. Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Rev Vaccines 2020;19:727-44. [PMID: 32702246 DOI: 10.1080/14760584.2020.1800462] [Reference Citation Analysis]
12 Kim HJ, Lee S, Koo YJ, Kwon E, Kim HJ, Choi JY, Kim JS. Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors. J Clin Neurol 2020;16:674-80. [PMID: 33029975 DOI: 10.3988/jcn.2020.16.4.674] [Reference Citation Analysis]
13 Cao Y, Shi H, Sun Z, Wu J, Xia Y, Wang Y, Wu Y, Li X, Chen W, Wang A, Lu Y. Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2. Front Pharmacol 2019;10:119. [PMID: 30971913 DOI: 10.3389/fphar.2019.00119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]